Pfizer to acquire Biohaven in $11.6bn deal to gain access to rimegepant

Pfizer has agreed to acquire Biohaven Pharmaceutical, a US-based biopharma company, in a deal worth around $11.6 billion, to gain access to the latter’s dual-acting ... Read More